Equipment and utensils are not cleaned and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product.
Inspection Record
Gilead Sciences Inc. — FDA 483 Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
Buildings used in the holding of a drug product are not maintained in a good state of repair.
Acceptance criteria for the sampling and testing conducted by the quality control unit is not adequate to assure that batches of drug products meet each appropriate specification and appropriate statistical quality control criteria as a condition for their approval and release.
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process.
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not followed.
Aseptic processing areas are deficient regarding systems for maintaining any equipment used to control the aseptic conditions.
Written procedures are not followed for evaluations conducted at least annually to review records associated with a representative number of batches, whether approved or rejected.
Laboratory controls do not include the establishment of scientifically sound and appropriate sampling plans and test procedures designed to assure that drug products conform to appropriate standards of identity, strength, quality and purity.
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to aseptic processing of drug products.
Similar findings at other companies
GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.
- Leiter's Enterprises, Inc. dba Leiter's2018-10-24 · US FDASimilar to finding 5 Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not followed.
- Zydus Lifesciences Limited2025-09-05 · US FDASimilar to finding 9 Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
- Granules Pharmaceuticals Inc.2026-04-03 · US FDASimilar to finding 2 Buildings used in the holding of a drug product are not maintained in a good state of repair.
- SSM Health Care St. Louis DBA SSM St. Clare Health Center2015-07-23 · US FDASimilar to finding 5 Procedures designed to prevent microbiological contamination of compounded drug products purporting to be sterile are not followed.
- PharMEDium Services, LLC2018-10-24 · US FDASimilar to finding 9 Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
A record as of the US FDA document published on 2024-01-17. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.